Evidence map›Paper›PMID 42880124›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Immune parameters in hospitalized COVID-19 patients during SARS-CoV2 delta and omicron waves.

Geraldo S Magalhães, Sarah N C Gimenes, Bianca C L F Távora, José A Portes Junior, Paula A L Calabria, Leonel I Montealegre-Sanchez, Sandra C Sampaio Vessoni, Eduardo Massad, Celina A Lamas, Sergio S Muller and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Geraldo S MagalhãesImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Sarah N C GimenesImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Bianca C L F TávoraImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
José A Portes JuniorImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Paula A L CalabriaImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Leonel I Montealegre-SanchezImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Sandra C Sampaio VessoniImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Eduardo MassadImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil.
Celina A LamasPulmonology Division, Institute of Heart, Hospital das Clínicas of the University of Sao Paulo Medical School (HCFMUSP) , Sao Paulo, SP, Brazil.
Sergio S MullerPulmonology Division, Institute of Heart, Hospital das Clínicas of the University of Sao Paulo Medical School (HCFMUSP) , Sao Paulo, SP, Brazil; Digital Health, Technological Innovation Center (InovaHC), University of Sao Paulo Medical School (HCFMUSP), Sao Paulo, SP, Brazil.
Tania Regina Tozetto-MendozaDepartment of Infections and Tropical Disease, School of Medicine, University of Sao Paulo (FMUSP), Sao Paulo, SP, Brazil; Virology Lab (LIM-52), Institute of Tropical Medicine, Medical School, University of Sao Paulo (FMUSP), Sao Paulo, SP, Brazil.
Maria Cássia Mendes-CorreaDepartment of Infections and Tropical Disease, School of Medicine, University of Sao Paulo (FMUSP), Sao Paulo, SP, Brazil; Virology Lab (LIM-52), Institute of Tropical Medicine, Medical School, University of Sao Paulo (FMUSP), Sao Paulo, SP, Brazil.
Carlos R R CarvalhoDigital Health, Technological Innovation Center (InovaHC), University of Sao Paulo Medical School (HCFMUSP), Sao Paulo, SP, Brazil.
Eliana L Faquim-MauroImmunopathology Lab, Butantan Institute, Sao Paulo, SP, Brazil. Electronic address: eliana.faquim@butantan.gov.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding immune mechanisms associated with COVID-19 severity remains important for interpreting clinical outcomes. We investigated virological and immunological profiles in 39-patients hospitalized with COVID-19 at InCor Hospital during the Delta and Omicron waves and included 28-non-hospitalized individuals with moderate COVID-19 as a comparator group for cytokine analyses. SARS-CoV-2 infection was confirmed by RT-PCR from nasopharyngeal swabs, and viral variants were identified by next-generation sequencing. RNAemia was assessed by RT-PCR and analyzed as a binary variable. Serum cytokines were quantified by cytometric bead array, while humoral responses were evaluated by anti-Spike RBD IgG levels using CLIA and a Wuhan-Hu-1-based pseudovirus neutralization assay. RNAemia was more frequent in ICU-admitted patients than in non-ICU patients, supporting an association with disease severity. Cytokine profiling showed increased IL-6, IL-8, TNF, IL-17 A and IL-10 levels in hospitalized patients compared with moderate COVID-19 individuals, but did not distinguish recovered from deceased patients. Neutralizing antibody titers measured against a Wuhan-Hu-1 spike pseudovirus were significantly higher in recovered individuals than decease patients, underscoring the relevance of antibody functionality. These data emphasize the relevance of viral dissemination and functional humoral immunity as potential biomarkers for COVID-19 progression and outcome, with RNAemia and neutralizing antibody levels showing a stronger exploratory association in this cohort.

Indexed as

Clinical outcomesCytokinesNeutralizing antibodiesRNAemiaSars-cov-2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.